Last reviewed · How we verify
ACAM2000 Smallpox Vaccine — Competitive Intelligence Brief
phase 2
Immunology
Biologic
Live · refreshed every 30 min
Target snapshot
ACAM2000 Smallpox Vaccine (ACAM2000 Smallpox Vaccine) — Emergent BioSolutions. ACAM2000 Smallpox Vaccine works by stimulating an immune response to the smallpox virus.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| ACAM2000 Smallpox Vaccine TARGET | ACAM2000 Smallpox Vaccine | Emergent BioSolutions | phase 2 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- ACAM2000 Smallpox Vaccine CI watch — RSS
- ACAM2000 Smallpox Vaccine CI watch — Atom
- ACAM2000 Smallpox Vaccine CI watch — JSON
- ACAM2000 Smallpox Vaccine alone — RSS
Cite this brief
Drug Landscape (2026). ACAM2000 Smallpox Vaccine — Competitive Intelligence Brief. https://druglandscape.com/ci/acam2000-smallpox-vaccine. Accessed 2026-05-15.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab